farnesyltransferase Inhibitors
1 drugsAbout farnesyltransferase
Farnesyltransferase (FTase) catalyzes the addition of a farnesyl group to proteins, a modification crucial for signaling protein localization and function. This farnesylation process impacts cell growth and differentiation pathways by modifying proteins near their C-terminus. FTase plays a key role in activating oncogenes like Ras.
While no genetic evidence directly links FTase to specific diseases, its role in modifying key signaling molecules makes it a relevant target. Inhibiting FTase blocks the farnesylation of proteins, potentially disrupting their signaling pathways and inhibiting cell growth. This mechanism has been explored in cancer.
Farnesyltransferase is targeted by one FDA-approved drug, ZOKINVY, a small molecule used in 'other' therapeutic areas. SENTYNL THERAPS INC is the sole company with an approved drug for this target. ZOKINVY was first approved in 2020.
Top farnesyltransferase Drugs
SENTYNL THERAPS INC is the only company with an approved drug targeting farnesyltransferase.
The lack of competition represents an opportunity, but also highlights potential market entry barriers.
farnesyltransferase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets farnesyltransferase, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
farnesyltransferase Clinical Trials 12 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on farnesyltransferase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 | - |
| Phase 2 | 9 | 8 | 1 | 0 | 89% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
farnesyltransferase Drug Approval Timeline (2020 - 2020)
The first and most recent drug approval for farnesyltransferase was ZOKINVY in 2020.
Recent approval suggests renewed interest, but limited timeline indicates potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on farnesyltransferase. A trial counts if an approved drug acting on farnesyltransferase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.